Zura Bio Limited ZURA
Updated: 10 Aug 2026
No signal published yet
We already track Zura Bio and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Zura Bio Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Zura Bio free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 29, 2026, Zura Bio announced that it exceeded enrollment targets in its Phase 2 TibuSHIELD and TibuSURE trials evaluating tibulizumab. Topline data from the TibuSHIELD study in hidradenitis suppurativa is expected in the fourth quarter of 2026. The company also announced plans to initiate a Phase 2 trial for a third immune-mediated indication by year-end 2026.
What Firelda Watch includes for Zura Bio Limited
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Zura Bio Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Zura Bio free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more